Yulin Red Cross Hospital
Welcome,         Profile    Billing    Logout  
 45 Trials 
93 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Yu
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting
3
366
RoW
RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda
RemeGen Co., Ltd.
Breast Cancer
06/24
12/24
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
NCT06258811: Neoadjuvant Immunochemotherapy for LAOSCC

Recruiting
3
134
RoW
albumin paclitaxel, cispatin, tislelizumab
Lai-ping Zhong, Sun Yat-sen University, Fudan University, Central South University, Fujian Medical University
Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
12/26
12/28
NCT02686151: The Letrozole Administration During Luteal Phase

Not yet recruiting
3
50
RoW
Letrozole, Femara, Polygeline, polyegline, Sodium Chloride, Natrum muriaticum, dexamethasone, dexametona
The Affiliated Hospital of Inner Mongolia Medical University
Ovarian Hyperstimulation Syndrome
03/24
12/24
NCT05921305: Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD

Recruiting
3
218
RoW
MTX, Corticosteroid
Peking University People's Hospital
Acute Graft Versus Host Disease
06/24
12/24
NCT06558981: Adjuvant Radiotherapy in High Risk Locally Advanced DTC

Recruiting
3
124
RoW
Radiotherapy, radioiodine treatment
Fudan University
Thyroid Cancer
06/31
06/31
NCT06108739: ATG Plus Low-dose PT-Cy for GVHD Prevention

Recruiting
3
196
RoW
Cyclophosphamid, ATG
Peking University People's Hospital
Hematologic Malignancy
12/24
06/25
NCT04612894: Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Not yet recruiting
2
31
RoW
Camrelizumab and Apatinib, surgery, core needle biopsy
Fudan University
Thyroid Cancer
12/22
12/23
NCT04958538: MTX and Steroid for III-IV aGVHD Treatment

Recruiting
2
30
RoW
Methotrexate, Corticosteroid
Peking University People's Hospital
Acute Graft Versus Host Disease
12/22
01/23
NCT04787328: A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)

Recruiting
2
30
RoW
HA121-28 tablets
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Medullary Thyroid Carcinoma
03/23
03/25
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

Recruiting
2
120
RoW
TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-alcoholic Steatohepatitis
12/26
12/27
NCT04583020: Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma

Recruiting
2
42
RoW
Camrelizumab, radiation, Temozolomide, TMZ
Peking Union Medical College Hospital, Jiangsu HengRui Medicine Co., Ltd.
Glioblastoma
12/23
12/23
NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

Terminated
2
85
Europe, US, RoW
LY3361237, Placebo
Eli Lilly and Company
Systemic Lupus Erythematosus
12/23
12/23
NCT06322394: BXOS110 Injection in the Treatment of Acute Ischaemic Stroke

Recruiting
2
300
RoW
high-dose BXOS110, BXOS110, low-dose BXOS110, Placebo
Biocells (Beijing) Biotech Co.,Ltd
Acute Ischemic Stroke
03/25
09/25
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Recruiting
2
129
RoW
ICP-488 Tablets, ICP-488 Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Moderate to Severe Plaque Psoriasis
10/24
11/24
NCT06494995: AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Not yet recruiting
2
52
RoW
Cadonilimab, Low-dose radiotherapy, SBRT, Capecitabine
Fudan University
Head and Neck Squamous Cell Carcinoma
07/26
07/28
NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Recruiting
2
120
RoW
HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets
Hansoh BioMedical R&D Company
Psoriasis
07/24
08/24
INSIGHT, NCT04995120: Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma

Recruiting
2
42
RoW
chemotherapy TP regimen combined with Toripalimab, Paclitaxel or Nab-Paclitaxel, Cisplatin
Fudan University
Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
12/24
12/25
NCT05420597: Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

Recruiting
2
61
RoW
Toripalimab, JS001
Fudan University
Laryngeal Cancer, Hypopharyngeal Cancer
12/24
12/25
NCT05422066: Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Hourglass Jan 2023 - Dec 2023 : Market entry for endometrial cancer
Recruiting
2
50
RoW
Selinexor, ATG-010, Xpovio, Rituximab, RiTUXimab Injection, Cyclophosphamide, Cyclophosphamide Injection, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product
Li Zhiming, Antengene Corporation
DLBCL Germinal Center B-Cell Type
07/25
12/25
NCT05989425: Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Recruiting
2
32
RoW
surufatinib
Fudan University
Differentiated Thyroid Cancer
08/26
08/26
NCT05842746: Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma

Not yet recruiting
2
74
RoW
Elemene, Placebo
Peking Union Medical College Hospital
Glioblastoma, IDH-wildtype
12/26
05/27
NCT06039631: Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

Recruiting
2
82
RoW
Surgery, Radiation, Toripalimab
Fudan University, Fudan University Eye Ear Nose and Throat Hospital, Shanghai Zhongshan Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Ruijin Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Larynx Cancer, Hypopharyngeal Cancer
09/27
09/29
NCT05102292: The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Active, not recruiting
1/2
25
RoW
HLX208, BRAF V600E inhibitor
Shanghai Henlius Biotech
Anaplastic Thyroid Cancer, ATC
06/24
12/24
NCT06167486: SG2918 For Advanced Malignant Tumors

Recruiting
1
117
RoW
SG2918
Hangzhou Sumgen Biotech Co., Ltd.
Advanced Malignant Tumors
12/25
12/26
KTX-MMSET-001, NCT05651932: A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Recruiting
1
125
Europe, Canada, US
Cohort A1 & A2, KTX-1001, Dexamethasone, Cohort C1 & C2, Carfilzomib, Cohort D, Pomalidomide
K36 Therapeutics, Inc.
Multiple Myeloma, Myeloma, Myeloma Multiple
12/25
06/26
NCT04312087: Lateral Neck Lymph Node Mapping in Thyroid Cancer

Recruiting
N/A
250
RoW
Lateral neck sentinel lymph node biopsy, Modified lateral neck lymph node dissection, Super selective lateral neck lymph node dissection
Fudan University
Thyroid Cancer
08/21
12/22
Pan-CHESS1802, NCT03713606: Serum Biomarkers for Portal Hypertension in Cirrhosis

Recruiting
N/A
75
RoW
HVPG measurement, Blood test
Nanfang Hospital of Southern Medical University, Beijing YouAn Hospital, Shandong Provincial Hospital, Beijing Shijitan Hospital, Capital Medical University, Beijing Friendship Hospital, Xingtai People's Hospital, Beijing 302 Hospital
Hypertension, Portal
01/22
06/22
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events

Recruiting
N/A
100000
RoW
Chinese Academy of Medical Sciences, Fuwai Hospital
Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment
12/22
12/23
SAFE-APD, NCT03598387: Automated Peritoneal Dialysis Versus Intermittent Hemodialysis in Acute Kidney Injury

Recruiting
N/A
100
RoW
Automated peritoneal dialysis, Intermittent hemodialysis
Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation
Acute Kidney Injury
12/22
12/22
URG-APD, NCT03754361: The Study of Efficacy and Safety of Automated PD in Urgent Start Dialysis

Recruiting
N/A
206
RoW
automated peritoneal dialysis, IHD
Peking Union Medical College Hospital, First Hospital of China Medical University, Beijing Anzhen Hospital, The Luhe Teaching Hospital of the Capital Medical University, Ningbo No.2 Hospital
ESRD
12/22
02/23
NCT04714918: Chinese CKD-MBD Prevalence Survey (CRISS-MBD)

Recruiting
N/A
10254
RoW
Limeng Chen
Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder
12/24
12/24
NCT05455099: A Multicenter Study of Ultrafast Pulse Wave Velocity in Obese Chinese Han Adults

Recruiting
N/A
2400
RoW
Carotid ultrasound examination 1, Carotid ultrasound examination 2
First Hospital of China Medical University
Carotid Artery Diseases
08/23
07/24
NCT06062914: Health Economic Research on Oral Nutritional Supplements for Hospitalized Patients With Nutritional Risk

Not yet recruiting
N/A
30000
RoW
oral nutritional supplements
Peking Union Medical College Hospital
Malnutrition, Nutritional Risk
11/23
11/23
NCT02432248: Effect of DHEA on Patients With Poor Ovarian Responds

Recruiting
N/A
350
RoW
Dehydroepiandrosterone, DHEA, placebo(medical starch)
The Affiliated Hospital of Inner Mongolia Medical University, First Affiliated Hospital, Sun Yat-Sen University, Renmin Hospital of Wuhan University
Subfertility
12/23
12/24
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program

Recruiting
N/A
16000
RoW
phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2
Wuhan Union Hospital, China, Peking University First Hospital
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease
12/23
12/24
NCT06524167: RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer

Recruiting
N/A
80
RoW
adjuvant radiotherapy
Fudan University
Thyroid Cancer
06/31
06/31
NCT06530316: RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer

Recruiting
N/A
48
RoW
RET Inhibitor, Surgery
Fudan University
Thyroid Cancer
12/26
12/29
NCT06623266: Neck Observation or Elective Neck Dissection in CT1N0M0 OSCC

Recruiting
N/A
300
RoW
Neck management
Huashan Hospital
Oral Cancer, Lymph Node Metastasis
09/26
09/28
COMPLETE Study, NCT06581081: Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for R/r B-cell Acute Lymphoblastic Leukemia

Recruiting
N/A
130
RoW
Senl_B19 autologous CAR-T (S1904) treatment
Peking University People's Hospital, The First Affiliated Hospital of Soochow University, Nanfang Hospital, Southern Medical University
Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
08/27
08/29
NCT05926323: Anesthesia Quality Control Indicators of 6 Provinces in Central China

Withdrawn
N/A
60000000
NA
Shanglong Yao
Anesthesia-related Quality Control Indicators, Anesthesia-related Adverse Events
12/24
12/25
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
chen, yan yan
HEARTRIP, NCT03809273: Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI

Recruiting
4
668
RoW
Yangxinshi, Trimetazidine, Yangxinshi mimic, Trimetazidine mimic
Shenyang Northern Hospital
Percutaneous Coronary Intervention
12/20
12/20
NCT05481619: Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis

Recruiting
4
30
RoW
Vedolizumab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ulcerative Colitis
01/24
01/24
NCT05205603: Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis

Recruiting
4
438
RoW
Infliximab, Vedolizumab, Mesalazine
Sixth Affiliated Hospital, Sun Yat-sen University
Ulcerative Colitis, Efficacy, Self, Biologics, Mesalazine
01/24
01/25
TIGER, NCT04255602: A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

Recruiting
4
2120
RoW
Ticagrelor 60mg, Ticagrelor 90mg
Shanghai Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Fudan University
Acute Coronary Syndrome, Coronary Stent Implantation
12/24
12/24
OPTIMA-6, NCT05410925: Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction

Recruiting
4
2260
RoW
Recombinant staphylokinase, Placebo
The First Affiliated Hospital with Nanjing Medical University
ST Elevation Myocardial Infarction
12/26
12/27
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Recruiting
3
388
RoW
HLX04-O,recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis
Shanghai Henlius Biotech
Age Related Macular Degeneration
08/23
03/24
TAPER-V, NCT04138706: Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection

Active, not recruiting
3
263
Canada
Vancomycin, Placebos
McGill University Health Centre/Research Institute of the McGill University Health Centre, Canadian Institutes of Health Research (CIHR)
Clostridium Difficile Infection
10/24
10/24
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
NCT06434467: The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

Not yet recruiting
3
83
RoW
Nelarabine injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma
12/25
05/26
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

Recruiting
3
368
Europe, US, RoW
SHR0302, Placebo
Reistone Biopharma Company Limited, Reistone Biopharma Company Limited
Ulcerative Colitis
10/24
03/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Recruiting
3
402
RoW
Vedolizumab IV, Placebo
Takeda
Moderately to Severely Active Ulcerative Colitis
05/28
07/28
BK2016.01, NCT03146637: Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

Recruiting
2
80
RoW
Activated CIK, CIK
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Beijing 302 Hospital
Advanced Liver Cancer
01/21
01/21
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT04633798: Evaluation of the Efficacy of Intense Pulse Light Combined With Lipiflow in the Treatment of Meibomian Gland Dysfunction

Not yet recruiting
N/A
100
NA
IPL/Lipiflow, IPL/MGX
Aier School of Ophthalmology, Central South University
Meibomian Gland Dysfunction
12/20
12/20
NCT03806621: Rota China Registry

Completed
N/A
980
RoW
Rotational Atherectomy
Beijing Anzhen Hospital, BSC International Medical Trading (Shanghai) Co., Ltd.
Coronary Artery Disease
12/20
01/22
NCT05777616: The Impact of Medication Belief on Adherence to Infliximab in Patients With Crohn's Disease

Completed
N/A
166
RoW
Second Affiliated Hospital, School of Medicine, Zhejiang University
Inflammatory Bowel Diseases
12/21
12/21
NCT05705856: Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease

Recruiting
N/A
200
RoW
Ustekinumab, UST, Ustekinumab antibody
Second Affiliated Hospital, School of Medicine, Zhejiang University
Crohn Disease
12/23
06/24
NCT06203782: Comparing Endoscopic Strictureplasty vs. Balloon Dilation in Crohn's Strictures

Not yet recruiting
N/A
102
NA
endoscopic stricturoplasty, endoscopic balloon dilation
Second Affiliated Hospital, School of Medicine, Zhejiang University
Crohn Disease
01/26
01/26
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice

Completed
N/A
500
RoW
Takeda
Colitis, Ulcerative, Crohn Disease
07/24
07/24
NCT05387031: Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease

Recruiting
N/A
239
RoW
Ustekinumab, Stelara
Second Affiliated Hospital, School of Medicine, Zhejiang University, Sixth Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital of Soochow University, Chongqing Renji Hospital, University of Chinese Academy of Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Seventh Medical Center of PLA Army General Hospital, First People's Hospital of Hangzhou, Yangzhou University, Xian-Janssen Pharmaceutical Ltd.
Crohn Disease, Stricture; Bowel, Intestinal Stricture
08/26
08/27
NCT05638269: A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China

Recruiting
N/A
12000
RoW
no intervention
Zhujiang Hospital, National Natural Science Foundation of China
Essential Hypertension, Liver Cancer, Nasopharyngeal Cancer, Pancreatic Cancer, Lung Cancer, Chronic Kidney Diseases, Acute Coronary Syndrome, Epilepsy, Gastric Cancer, Primary Aldosteronism, Subclinical hypothyroïdism
12/24
12/25
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting
N/A
184
RoW
Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Coronary Artery Disease, Intravascular Lithotripsy
12/24
09/25
CAM Cohort, NCT06798077: Chronic Airway Disease and Miltimorbidity Cohort

Not yet recruiting
N/A
2000
RoW
China-Japan Friendship Hospital, Second Affiliated Hospital of Xi'an Jiaotong University, First Hospital of China Medical University, Henan Provincial People's Hospital, Second Xiangya Hospital of Central South University, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Sichuan University, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis
07/28
07/28
NCT04390971: Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia

Active, not recruiting
N/A
3
RoW
ET-01
Institute of Hematology & Blood Diseases Hospital, China, EdiGene Inc., The Affiliated Hospital Of Guizhou Medical University, Zunyi Medical College
Transfusion Dependent Beta-Thalassaemia
06/25
08/25
NCT04212494: Thrombus Aspiration in STEMI Patients With High Thrombus Burden

Recruiting
N/A
3838
RoW
Thrombus aspiration, PCI Alone
Guangdong Provincial People's Hospital, Zhongshan People's Hospital, Guangdong, China, Kaiping Central Hospital, The Second Affiliated Hospital of Shantou University Medical College, The Third Xiangya Hospital of Central South University, Sihui City People's Hospital, Shenzhen Baoan District Shiyan People's Hospital, People's Hospital of Nanxiong County, Yuebei People's Hospital, Weifang Medical University, Wuzhou Gongren Hospital, Dafeng Hospital of Chaoyang District in Shantou City, Shenzhen Baoan People's Hospital, Dongguan People's Hospital, Yangchun People's Hospital, Taishan People's Hospital, The Second People's Hospital of Foshan, Guangzhou Hospital of integrated Traditional and West Medicine, Guangning People's Hospital, Foshan Sanshui District People's Hospital, Qingyuan People's Hospital, Luhe County People's Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The Fourth People's Hospital of Chenzhou, People's Hospital of Dapu County, Shenzhen People's Hospital, Heyuan people's Hospital, Huaiji People's Hospital, People's Hospital of Yingde City, Qingyuan Hospital of Traditional Chinese Medicine Affiliated To Guangzhou University of Traditional Chinese Medicine, Zhongshan Hospital Of Traditional Chinese Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Lianzhou People's Hospital, Lianping Xian Ren Ming Yi Yuan, Guangxi Zhuang Autonomous Region Nationalities Hospital, Liuzhou Municipal Liutie Central Hospital, Chen Zhou 3RD People's Hospital, Longgang District Central Hospital of Shenzhen, The Affiliated Shunde Hospital of Jinan University, Shenzhen Longhua District Central Hospital, Shantou Central Hospital, Tongxiang First People's Hospital, Bobai County People's Hospital, Guangxi, Meizhou Traditional Chinese Medicine Hospital, The Third Affiliated Hospital of Sun Yat-Sen University, Yuedong Hospital, Shenzhen Third People's Hospital, Yangjiang People's Hospital, Jiangmen Central Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, The First People's Hospital of Kashgar Erea, First People's Hospital of Foshan, Zhaoqing Gaoyao People's Hospital, People's Hospital of Nanhai District, Foshan, The Second Affiliated Hospital of Dalian Medical University, Nanning Second People's Hospital, The Second People's Hospital of Nanhai District of Foshan, Shangyou People's Hospital
ST-segment Elevation Myocardial Infarction (STEMI)
08/25
02/26
NCT04912401: the Efficacy and Safety of Etanercept (Yi Sai Pu) in Chinese Patients With Moderate-to-Severe Psoriasis

Recruiting
N/A
100
RoW
Second Affiliated Hospital, School of Medicine, Zhejiang University
Psoriasis, Etanercept
12/25
12/25
NCT05719766: Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients

Not yet recruiting
N/A
200
RoW
education ,psycological support and social support
Second Affiliated Hospital, School of Medicine, Zhejiang University
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
01/27
02/27
NCT04933214: Adherence to Exclusive Enteral Nutrition in Patients With Crohn's Disease

Recruiting
N/A
131
RoW
Second Affiliated Hospital, School of Medicine, Zhejiang University
Crohn Disease
12/21
12/21
Zhang, Hua
NCT03476083: Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission

Recruiting
4
280
RoW
Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily., HBIg 200 IU im for infants in the group B, HBV vaccine 10 ug im for all infants
New Discovery LLC
Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia, Chronic Infection
05/21
05/24
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Completed
3
159
RoW
SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592
FibroGen
Chemotherapy Induced Anemia
04/23
04/23
AK0529-2007, NCT06775405: A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants

Recruiting
3
180
RoW
AK0529, Placebo
Shanghai Ark Biopharmaceutical Co., Ltd.
Respiratory Synctial Virus Infections
08/25
09/25
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

Recruiting
2
261
RoW
Recombinant humanized IL-17A Monoclonal Antibody(JS005), Placebo(JS005)
Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH
Ankylosing Spondylitis
02/25
10/25
NCT06451640: A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps

Recruiting
2
60
RoW
210mg of TQC2731 injection, 420mg of TQC2731 injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Chronic Rhinosinusitis With Nasal Polyps
05/25
02/26
NCT06439381: Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps

Recruiting
2
120
RoW
300mg/600mg of TQH2722 injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Rhinosinusitis
10/25
11/25
NCT06617936: Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Recruiting
2
35
RoW
neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy, surgery, Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar), Standard Treatment
Hua Zhang
Unresectable Non-small Cell Lung Cancer
08/25
09/27
NCT06657391: Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia

Recruiting
2
396
RoW
recombinant humanized anti-CD25 monoclonal antibody
Rongrong Liu
Transfusion Dependent Thalassemia
09/27
09/27
NCT06709859: Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Not yet recruiting
2
30
RoW
Afatinib plus chemotherapy as conversion treatment
Shandong Public Health Clinical Center
Carcinoma, Non-Small-Cell Lung
05/26
12/27
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Recruiting
2
280
RoW
Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd.
Non-small Cell Lung Cancer
02/25
02/28
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.

Recruiting
2
160
RoW
300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Sinusitis
05/25
05/25
NCT06036927: A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps

Recruiting
2
80
RoW
TQC2731 injection, TQC2731 matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Sinusitis, Nasal Polyps
07/25
09/25
NCT06241521: Myasthenia Gravis Registry in China

Recruiting
N/A
1500
RoW
Huashan Hospital, China Alliance for Rare Diseases, National Center for Neurological Disorders (China), China myasthenia gravis collaborating group (CMGCG)
Myasthenia Gravis
02/34
01/35
MISET-TLE, NCT05019404: Minimally Invasive Surgical Epilepsy Trial for Temporal Lobe Epilepsy

Recruiting
N/A
120
RoW
Functional anterior temporal lobectomy (FATL), Anterior temporal lobectomy (ATL)
First Affiliated Hospital Xi'an Jiaotong University
Temporal Lobe Epilepsy, Open Surgery, Minimally Invasive Surgery
09/24
09/25
NCT05172453: Mother-to-child Transmission of HBV in China

Recruiting
N/A
50000
RoW
comprehensive management algorithm for preventing mother-to-child transmission of HBV
Nanfang Hospital of Southern Medical University, Chinese Foundation for Hepatitis Prevention and Control, Tigermed Consulting Co., Ltd
Hepatitis B, Chronic, Mother to Child Transmission
06/25
12/25
Yao, Bingna
NCT06606509: The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).

Not yet recruiting
N/A
1000
RoW
Continuous Glucose Monitoring System (GX-01S)
Nanjing First Hospital, Nanjing Medical University
Type1 Diabetes Mellitus
10/26
06/27

Download Options